Cleveland HeartLab New Leadership 2012

Cleveland Heartlab Press Releases

Jake Orville
President & Chief Executive, Cleveland HeartLab Inc.

Jason Lansdale
Marketing Manager, Cleveland HeartLab Inc.
216-426-6081, ext. 1450

Rod Hise
The Luminis Group, Ltd. for Cleveland HeartLab Inc.

For Immediate Release

Cleveland HeartLab expands scientific, sales leadership teams with appointment of three key executives
CLEVELAND, Aug. 7, 2012 – Cleveland HeartLab Inc. (CHL), a rapidly growing specialty clinical laboratory and cardiovascular disease management company, today announced three additions to its team that will enable the company to continue to set new standards of growth, customer service and innovation.

Deborah H. Sun, Ph.D., has been appointed vice president of laboratory operations. Dr. Sun has more than 20 years of experience in the field of clinical laboratory management. She was most recently scientific director of clinical pathology at South Bend Medical Foundation, Sound Bend, Ind., a regional clinical laboratory serving physicians and patients in five states. As scientific director, she oversaw the research department, led the development of new tests and testing technologies, directed the quality assurance unit, and provided technical leadership and consultation to a variety of functions within the organization. Dr. Sun earned her Ph.D. in clinical chemistry from Cleveland State University, and completed her postdoctoral training in Clinical Chemistry under Dr. Norbert Tietz, who is a well-known contributor in the field of laboratory medicine.

Cory Bystrom, Ph.D., has been appointed director of research and development. Dr. Bystrom brings more than a decade of experience as a laboratory leader and chemist to his new role at CHL. He joins the company from Quest Diagnostics Nichols Institute, San Juan Capistrano, Calif., a world leader in highly specialized laboratory testing, where he was associate director of research and development. In his role at Quest, he led a team in the development and operational scale-up of new tests, identified new testing technologies to improve productivity and assessed potential new markers. He also has held research and development roles at Oregon Health Science University, Pharmacia Corp., and Upjohn. He earned his Ph.D. in chemistry from the University of Oregon.

“The addition of Dr. Deborah Sun and Dr. Cory Bystrom to the Cleveland HeartLab team will expand and accelerate our continuing efforts to develop and commercialize proprietary tests based on significant, unmet needs in the market,” said Jake Orville, president and chief executive of Cleveland HeartLab. “Their experience developing important new tests and overseeing their scale-up to commercialization will be invaluable to us as Cleveland HeartLab continues to establish itself as a preeminent specialty clinical laboratory and disease management company.”

Stephen A. Massaro has been appointed vice president of sales. Mr. Massaro brings over twenty years of sales management experience to CHL. He was most recently area vice president of sales for Smiths Medical, a global leader in medical devices, where he led a $200-million commercial sales organization. Prior to his position as area vice president, Mr. Massaro held several key national sales leadership roles at Smiths Medical, and was recognized for his leadership and performance. Mr. Massaro also held sales management positions with Davis & Geck and U.S. Surgical (now Covidien PLC). He earned a Bachelor of Business Administration degree in marketing from Bloomsburg University of Pennsylvania.

“We are delighted to welcome Steve to Cleveland HeartLab,” Mr. Orville said. “He brings a demonstrated commitment to sales execution and that will help fuel our continued growth and success. Steve, Deborah and Cory join an outstanding leadership team at Cleveland HeartLab. Their expertise and talents, combined with those on our existing team, are exactly what we need to fully realize.”

About Cleveland HeartLab

Cleveland HeartLab Inc. is a specialty clinical laboratory and cardiovascular disease management company focused on offering a robust menu of propriety diagnostic tests based on unique molecular biomarkers. CHL operates a CLIA-certified and CAP-accredited clinical laboratory. It has developed a panel of tests that thousands of practitioners use in the management and prevention of heart disease. CHL also runs a research and development laboratory where next-generation cardiovascular disease biomarkers are being developed for use through CHL’s clinical laboratory. This valuable pipeline of tests is part of an exclusive intellectual property portfolio that targets large, under-addressed markets. For more information about Cleveland HeartLab, please visit the company’s website at